Asthma remains a difficult disease to treat and control, with a large portion of the patient population not receiving adequate treatment options. But next-generation therapies are targeting this inflammation by being more targeted, getting at the root of the pathways that play a larger role in the disease. Bob Baltera, chief executive officer of Amira Pharmaceuticals, tells host Bruce Japsen about developments in more targeted therapies.